Numatol

Citicoline

Method of action: Neurometabolic, Nootropic, Psychoanaleptics

Treatment option: Cerebrovascular Accident

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Numatol

Quick Facts

Property	Description
Active Ingredient	Citicoline (CDP-Choline)
Form	Oral solution, Tablets, Solution for Injection
Pharmacological Class	Nootropic, Neuroprotectant, Psychostimulant (Indirect)
General Purpose	Supports neurological structure and function
Origin	Synthetic compound
Differentiation	Structural precursor to cell membrane components

What Type of Medicine is Numatol? (Definition and Classification)

Numatol is a prescription-only medicinal product, defined by its sole active ingredient, Citicoline (Cytidine Diphosphate-Choline or CDP-Choline). Pharmacologically, it is classified as a neuroprotectant and a nootropic, a designation reserved for compounds intended to support the structural and functional health of the central nervous system. Citicoline is recognized globally in the Anatomical Therapeutic Chemical (ATC) classification system as a psychostimulant and nootropic. The substance is chemically identical to an endogenous nucleoside naturally found in the body, but it is supplied as an exogenous, synthetic compound to ensure pharmaceutical purity and consistency.

Citicoline: Composition, Origin, and Available Forms

The composition of Numatol relies entirely on the high-purity Citicoline compound, often formulated as the sodium salt, making it a single-component product. Numatol is available in multiple dosage forms, including both oral solutions and tablets, as well as solutions for parenteral administration via intravenous and intramuscular injection. The range of available forms, utilizing an aqueous solution as a base for liquids, ensures the substance can be effectively delivered into the system based on patient needs.

What is the General Purpose of Numatol? (High-Level Function)

The general purpose of Numatol is to provide comprehensive support for neuronal membrane stability and repair. Citicoline functions uniquely as a structural precursor, supplying the necessary choline and cytidine moieties required for the body's synthesis of phosphatidylcholine, a major phospholipid component of all nerve cell membranes. This mechanism is supported by pharmacological studies demonstrating its role in cellular repair and renewal. The general benefit of this action is the preservation of neuronal integrity, which is broadly utilized as a supportive measure in maintaining optimal neurological function.

What side effects are possible with Numatol?

Possible Side Effects and Safety Information

The official safety profile for Numatol (Citicoline) is generally characterized by a low toxicity profile, with most adverse reactions reported as very rare (occurring in fewer than 1 in 10,000 users) in regulatory documents. The possible effects are grouped by the body systems they impact, as noted in the Summary of Product Characteristics (SmPC) and prescribing information.

Documented Adverse Reactions

The most frequently documented adverse effects relate to the Gastrointestinal and Nervous Systems.

System-Organ Class	Examples of Listed Effects
Gastrointestinal Disorders	Nausea, diarrhea, constipation, stomach pain, or epigastric distress.
Nervous System Disorders	Headache, dizziness, restlessness, insomnia (trouble sleeping).
Vascular/Cardiac Disorders	Fleeting and discrete hypotension (low blood pressure), arterial hypertension, and changes in heart rate (tachycardia or bradycardia).

Serious adverse reaction tiers are not uniformly documented across major labels for this compound. Regulatory texts consistently advise that patients should seek medical attention immediately at the first sign of any adverse drug reaction.

Population-Specific Safety and Restrictions

Specific contraindications limit the use of Numatol. The medicine must not be used in individuals with a known hypersensitivity to Citicoline or any component of the formulation. It is also contraindicated in patients with hypertonia of the parasympathetic nervous system.

For specific patient populations, safety data is often noted as insufficient. Use during pregnancy and lactation is generally limited to situations where the potential benefit to the mother justifies the unknown risks. Furthermore, regulatory advisories note that use in children is typically not intended due to the lack of sufficient safety data.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation indicates that Numatol (Citicoline) has a very low toxicity profile in humans, establishing a wide margin of safety. While the substance is generally well-tolerated even at doses significantly higher than typical therapeutic ranges, overdose may present with documented clinical manifestations.

Documented Overdose Manifestations

System	Manifestations Listed in Regulatory Labels
Cardiovascular	Hypotension, Tachycardia, ECG changes, Ventricular arrhythmias
Central Nervous System	Drowsiness, Loss of consciousness, Severe extrapyramidal dyskinesias

Required Emergency Actions

Patients must seek medical attention immediately upon suspicion of an overdose or at the first sign of any related adverse drug reaction. Treatment for Numatol overdosage is defined as symptomatic and supportive. Regulatory information explicitly states that no specific antidote is known for Citicoline.

Management procedures, when clinically appropriate, may include attempted gastric lavage if the ingestion is recent, and the administration of activated charcoal. Pharmacological induction of emesis is not considered effective in this context. The official guidance emphasizes that continuous monitoring for potential cardiac effects, such as ventricular arrhythmias, may be required.

Therapeutic Uses of Numatol

What Numatol Treats: Main Uses and Benefits

Numatol is applied across domains where additional symptomatic support is needed in situations where patients experience neurological and cerebrovascular conditions. It is considered relevant in contexts involving cerebrovascular disease, head trauma, cognitive impairment, Parkinson's Disease, and glaucoma.

The primary therapeutic benefit may be relevant across conditions involving episodic or fluctuating manifestations. In acute scenarios associated with acute or disruptive episodes, such as stroke or Traumatic Brain Injury (TBI), Numatol is applied when supportive symptom management is appropriate. In chronic contexts, the medication assists with managing symptom clusters that may become intense or disruptive, such as memory loss, reduced attention, and slowed mental processing.

It provides support that helps ease the overall symptom burden and assists with maintaining functional stability.

“This application supports patients during difficult episodes by helping them cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Cognitive Strain The medication is commonly used to help manage symptoms that interfere with daily functioning and create noticeable physiological strain, particularly symptoms of increased neurological or muscular activity.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Numatol? (Official Regulatory Status)

Official regulatory documents define the populations permitted, restricted, or prohibited from using Numatol (Citicoline).

Classification	Rule (As Stated in Official Labeling)
Absolute Contraindication	Patients with hypertonia of the parasympathetic nervous system [Source 1.1].
Absolute Contraindication	Patients with known hypersensitivity to Citicoline or any component of the preparation [Source 3.1].

Restricted and Age-Based Eligibility

Use of Numatol in certain populations is subject to specific cautions or is restricted due to limited safety data:

Pediatric Use (Children): Experience is officially documented as limited in children. Administration is restricted and must only occur if the potential benefit for the child outweighs any potential risk [Source 4.4].
Pregnancy and Lactation: Due to a lack of adequate safety studies, use by pregnant or breastfeeding women is restricted and contingent upon the potential benefit strictly justifying the potential risk to the fetus or baby [Source 3.1].
Older Adults (Elderly): Use is permitted for older adults, and regulatory data confirms that no mandatory dose adjustment is required for this age group [Source 4.3].

Populations Requiring Caution

Administration requires caution in specific patient groups, as listed in the drug's prescribing information:

Patients with persistent intracranial hemorrhage [Source 1.1].
Patients with Parkinson’s disease [Source 4.4].
Patients with a history of depression (depression in anamnesis) [Source 4.4].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory interaction profile for Numatol is primarily defined by a mandatory contraindication and one documented pharmacodynamic effect.

Contraindicated Combination

Co-administration of Numatol with medicinal products containing Meclofenoxate (also known as Clophenoxate) is strictly prohibited. This combination is formally designated as a contraindicated combination in official regulatory labeling. This is an explicit, mandatory restriction that prohibits the concurrent use of Numatol with any substance containing Meclofenoxate.

Pharmacodynamic Interactions

Numatol is also documented to interact with the medicinal product L-dopa (Levodopa). The regulatory statement classifies this as a pharmacodynamic interaction, noting that co-administration may potentiate the effects of L-dopa. This means the pharmacological activity of L-dopa is officially documented as being increased when taken simultaneously with Numatol.

Absence of Pharmacokinetic or Timing Restrictions

Official regulatory documentation does not cite formal restrictions related to administration timing, nor does it specify interactions with food, alcohol, or common herbal products. Furthermore, there are no officially documented interactions mediated by major drug transporters or metabolic enzyme systems such as the Cytochrome P450 (CYP) enzymes that modify drug exposure. The profile does not contain specific cautions regarding the interaction severity in defined patient populations.

Mechanism of Action

Numatol is a synthetic protein that acts as an analog to osteoprotegerin ( OPG). Its biological target is Receptor Activator of Nuclear factor kappa B Ligand ( RANKL). Numatol binds to RANKL with high affinity, forming a stable complex. This binding interaction prevents RANKL from engaging its cognate receptor, RANK, which is expressed on the surface of osteoclast precursor cells. The blocked RANKL/ RANK interaction results in the suppression of the NF-kappa B signaling pathway. This key pathway modulation interrupts the molecular and intracellular cascades necessary for the differentiation, activation, and survival of osteoclasts. The consequence of this targeted inhibition is a reduction in the overall number and activity of mature osteoclasts. The resulting system-level physiological consequence is a decrease in the rate of bone resorption within the bone remodeling unit.

Dosage and Administration Information

How to Use Numatol

The use of Numatol (Citicoline) is structured around instructions detailing the approved routes, dosage ranges, and specific administration conditions.

Administration Scope

Instruction	Detail
Route of administration	Administration is approved via the Oral (tablets, solution), Intravenous (IV), and Intramuscular (IM) routes.
Dosing schedule	The total official daily dose typically ranges from 500 mg to 2000 mg, with parenteral use often utilizing the lower end of this range.
Timing in relation to meals	Oral dosage forms may be taken with food or between meals, providing flexibility for patient intake.
Preparation requirements	Oral solutions can be ingested directly or mixed with approximately 120 mL of water for consumption.
Age-group administration rules	The standard adult dose applies to older adults, as no specific dosage adjustment is generally required for this population.
Special procedural conditions	Direct IV administration must be performed very slowly over a period of 3 to 5 minutes. For specific clinical scenarios, the IV dose must not exceed 1000 mg/24h and must be administered as an extremely slow infusion (e.g., 30 drops/minute).

Connection to the Overall Use Protocol

The administration guidelines establish a standardized protocol centered on three approved delivery routes (oral, IV, IM) to ensure flexibility in a supportive care setting. These parameters formalize the use of the drug by specifying the daily consumption range of 500 mg to 2000 mg, along with the required frequency of once or twice daily. The detailed instructions on slow IV administration and the rule that oral forms can be taken independently of meal times define the necessary procedural steps for correct drug administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Numatol

Evidence for Use in Acute Ischemic Stroke

Numatol was studied in the context of conditions associated with acute or disruptive episodes, specifically in the context of an ischemic stroke. Research in this area primarily includes large, multi-center Randomized Controlled Trials (RCTs) and comprehensive meta-analyses that compared Numatol against a placebo. The main focus was evaluated in adult patients in the days immediately following a stroke, and research examined outcomes related to functional balance and activity level.

Some large-scale, pooled analyses of patient data data show patterns related to the overall recovery for individuals who experienced moderate to severe strokes. However, specific definitive trials reported that primary outcome measures did not show a statistically significant difference when assessing the general population of stroke patients. The certainty surrounding this evidence remains low due to the variable findings across major trials.

Evidence for Use in Cognitive Impairment

Numatol was evaluated in research contexts involving conditions characterized by functional limitations related to memory and mental processing, such as age-associated memory impairment and Mild Cognitive Impairment (MCI). Research in this area mainly consists of shorter-term RCTs that monitored changes in specific mental tasks and scores. These studies explored how symptoms were measured in the observed populations, with a focus on outcomes reflecting daily functioning and attention span.

Limited evidence was observed in some studies that had limited sample sizes, reporting data show patterns related to specific metrics of attention and some types of memory performance. However, the evidence quality varies across studies due to differences in how cognitive function was measured. The research provides limited insight into long-term outcomes or whether Numatol affects the progression of age-related memory decline over many years.

What is Still Uncertain about Numatol Evidence

Across all indications, the research highlights areas where more data are needed. Long-term effects are not fully established, as follow-up durations were limited in many key RCTs. Subgroup findings are uncertain, and findings were mixed or inconsistent in some major disease areas, leading to low certainty regarding broad, universal application.

Key Studies & References

Efficacy and safety of citicoline in patients with chronic cerebral circulation insufficiency: a randomized controlled trial

Frequently Asked Questions (FAQ)

Common questions about Numatol (FAQ)

Q: How often should I take Numatol—once or twice a day?

According to the official regulatory guidelines for Numatol, the required administration frequency is typically either once or twice daily. The specific schedule is intended to be determined by a prescriber to align with the patient's individual treatment plan.

Q: Is Numatol ever used in clinical practice for Parkinson's disease?

Official regulatory documents do not list Parkinson's disease as an approved indication (use) for Numatol. However, these documents do state that the medicine requires caution when administered to patients with this condition. Use in this context is subject to a medical professional's clinical judgment and risk assessment.

Q: What happens if I take Numatol at the same time as Meclofenoxate?

Co-administration of Numatol with medicinal products that contain Meclofenoxate (Clophenoxate) is strictly prohibited. This is an explicit mandatory restriction, as official product information formally designates this pairing as a contraindicated combination. Patients should ensure prescribers are fully aware of all concurrent medications.

Q: Is Numatol an over-the-counter supplement, or is it prescription-only?

Numatol is classified as a prescription-only medicinal product. Therefore, obtaining Numatol requires a valid prescription from a licensed healthcare provider.

Q: If I miss a dose of Numatol, what should I do?

Official instructions for use state that a double dose should not be taken to make up for a missed dose. Patients are generally directed to take the next scheduled dose as planned and continue with their treatment regimen.

Q: Is there a specific food I should avoid eating while taking this medicine?

Official regulatory documentation for Numatol does not cite formal restrictions regarding specific interactions with common foods, drinks, or herbal products. The medicine may be taken with food or between meals, providing flexibility for patient intake.

How should Numatol be stored and disposed of?

Storage Conditions

Numatol must be stored in accordance with official regulatory requirements to ensure its stability. The product, including oral solutions and tablets, must be stored at a temperature not exceeding 30 C. The medicine must be kept in its original package to protect it from moisture and light, and the container for the oral solution should be kept tightly closed.

Handling and Stability

For the injectable solution, storage must protect it from freezing. Unused portions of the injectable solution must be discarded immediately after opening, as it is a single-use presentation. The medicine must not be used after the expiry date printed on the packaging.

Disposal of Unused Medicine

Official disposal protocols require that Numatol must not be discarded via wastewater or general household waste to prevent environmental contamination. All unused or expired medicine must be returned to a pharmacist or disposed of through established local pharmaceutical waste programs.